Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (DE:22UA)
XETRA:22UA
22UA Analyst Ratings
Strong Buy
13 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
22UA Stock 12 Month Forecast
Average Price Target
€117.99
▲(32.27% Upside)
| Highest Price Target€157.03 | Average Price Target€117.99 | Lowest Price Target€92.83 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Canaccord Genuity
€146.92
Buy
64.71%
Upside
Reiterated
10/30/25
J.P. Morgan
€103.96→€103.1
Hold
15.59%
Upside
Reiterated
10/23/25
Bank of America Securities
€115.13→€111.69
Buy
25.22%
Upside
Reiterated
10/22/25
Wells Fargo
€128.88
Buy
44.48%
Upside
Reiterated
10/21/25
Citi
€120.29
Buy
34.85%
Upside
Reiterated
10/17/25
Morgan Stanley
€114.98→€112.55
Buy
26.18%
Upside
Reiterated
10/13/25
TD Cowen
€103.1
Hold
15.59%
Upside
Reiterated
10/02/25
BMO Capital
€122.86
Buy
37.74%
Upside
Reiterated
09/30/25
Clear Street
€158.95
Buy
78.20%
Upside
Reiterated
09/19/25
Truist Financial
―
Buy
―
Reiterated
09/09/25
Leerink Partners
€91.93
Buy
3.06%
Upside
Reiterated
09/09/25
Analysts Are Bullish on These Healthcare Stocks: McKesson (MCK), BioNTech SE (BNTX)We believe that preliminary global dose optimization outcomes with BioNTech (BNTX, OP) / BMY’s (OP, Risinger) VEGFA/PD-L1 bispecific pumitamig (pumi, BNT327) in combination with chemo in 1L ES-SCLC were exactly that: preliminary. Our enthusiasm remains unchanged—modestly optimistic—until we see a more mature dataset that provides a better look at important duration / survival outcomes key to estimating likelihood of pumi + chemo success in the ongoing, randomized Ph 3 trial, ROSETTA-Lung-01. Albeit in a small sample size, we are encouraged to see that these first global efficacy and promising safety outcomes with pumi in SCLC were largely consistent with those reported from the China-only trial.
H.C. Wainwright
€116.85
Buy
31.00%
Upside
Reiterated
09/08/25
Jefferies
€129.74
Buy
45.45%
Upside
Reiterated
08/05/25
Deutsche Bank
€120.29
Buy
34.85%
Upside
Reiterated
08/05/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Canaccord Genuity
€146.92
Buy
64.71%
Upside
Reiterated
10/30/25
J.P. Morgan
€103.96→€103.1
Hold
15.59%
Upside
Reiterated
10/23/25
Bank of America Securities
€115.13→€111.69
Buy
25.22%
Upside
Reiterated
10/22/25
Wells Fargo
€128.88
Buy
44.48%
Upside
Reiterated
10/21/25
Citi
€120.29
Buy
34.85%
Upside
Reiterated
10/17/25
Morgan Stanley
€114.98→€112.55
Buy
26.18%
Upside
Reiterated
10/13/25
TD Cowen
€103.1
Hold
15.59%
Upside
Reiterated
10/02/25
BMO Capital
€122.86
Buy
37.74%
Upside
Reiterated
09/30/25
Clear Street
€158.95
Buy
78.20%
Upside
Reiterated
09/19/25
Truist Financial
―
Buy
―
Reiterated
09/09/25
Leerink Partners
€91.93
Buy
3.06%
Upside
Reiterated
09/09/25
Analysts Are Bullish on These Healthcare Stocks: McKesson (MCK), BioNTech SE (BNTX)We believe that preliminary global dose optimization outcomes with BioNTech (BNTX, OP) / BMY’s (OP, Risinger) VEGFA/PD-L1 bispecific pumitamig (pumi, BNT327) in combination with chemo in 1L ES-SCLC were exactly that: preliminary. Our enthusiasm remains unchanged—modestly optimistic—until we see a more mature dataset that provides a better look at important duration / survival outcomes key to estimating likelihood of pumi + chemo success in the ongoing, randomized Ph 3 trial, ROSETTA-Lung-01. Albeit in a small sample size, we are encouraged to see that these first global efficacy and promising safety outcomes with pumi in SCLC were largely consistent with those reported from the China-only trial.
H.C. Wainwright
€116.85
Buy
31.00%
Upside
Reiterated
09/08/25
Jefferies
€129.74
Buy
45.45%
Upside
Reiterated
08/05/25
Deutsche Bank
€120.29
Buy
34.85%
Upside
Reiterated
08/05/25
Best Analysts Covering BioNTech SE
1 Month
xxx
Success Rate
14/25 ratings generated profit
Average Return
+1.34%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.00% of your transactions generating a profit, with an average return of +1.34% per trade.
3 Months
xxx
Success Rate
13/26 ratings generated profit
Average Return
+2.11%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +2.11% per trade.
1 Year
Success Rate
14/25 ratings generated profit
Average Return
+1.18%
reiterated a buy rating 2 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 56.00% of your transactions generating a profit, with an average return of +1.18% per trade.
2 Years
xxx
Success Rate
15/25 ratings generated profit
Average Return
+0.70%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +0.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
22UA Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
8
6
4
3
4
Buy
50
42
36
26
29
Hold
17
16
18
15
19
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
75
64
58
44
52
Each month's total comprises the sum of three months' worth of ratings.
22UA Financial Forecast
22UA Stock Forecast FAQ
What is DE:22UA’s average 12-month price target, according to analysts?
Based on analyst ratings, BioNTech SE’s 12-month average price target is 117.99.
What is DE:22UA’s upside potential, based on the analysts’ average price target?
BioNTech SE has 32.27% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BioNTech SE a Buy, Sell or Hold?
BioNTech SE has a consensus rating of Strong Buy, which is based on 13 buy ratings, 4 hold ratings and 0 sell ratings.
What is BioNTech SE’s share price target?
The average share price target for BioNTech SE is 117.99. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €157.03 ,and the lowest forecast is €92.83. The average share price target represents 32.27% Increase from the current price of €89.2.
The highest analyst share price target is €157.03 ,and the lowest forecast is €92.83. The average share price target represents 32.27% Increase from the current price of €89.2.
What do analysts say about BioNTech SE?
BioNTech SE’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of BioNTech SE?
To buy shares of DE:22UA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.